Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPR...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jiangxue, Li, Yufu, Lin, Quande
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463662/
https://www.ncbi.nlm.nih.gov/pubmed/37633955
http://dx.doi.org/10.1186/s40164-023-00436-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463662/
https://www.ncbi.nlm.nih.gov/pubmed/37633955
http://dx.doi.org/10.1186/s40164-023-00436-9

Ejemplares similares